Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol

Phase 2

• Conditions: Psoriasis Vulgaris

• Registration Number: NCT00678756
• Lead Sponsor: Technische Universität Dresden

Brief Summary

Exploration of antipsoriatic effects of UVB-therapy +/- CYP-inhibitor Ketokonazol on affected psoriatic skin

Detailed Description

Not available

Study Timeline

• Study Start: 2008-03
• Study First Submitted: 2008-05-14
• Study First Submitted QC: 2008-05-14
• Study First Posted: 2008-05-16
• Primary Completion: 2009-10
• Study Completion: 2009-12
• Status Verified: 2010-06
• Last Update Submitted: 2010-06-07
• Last Update Posted: 2010-06-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• age: 18- 80
• diagnosis of psoriasis vulgaris (mild- middle)
• no other current antipsoriatic therapy (systemic/topical)
• at least 5 psoriatic areas of 5x5 cm

Exclusion Criteria

• pregnancy/nursing mothers
• women in reproductive age without adequate contraception
• severe and acute forms of psoriasis vulgaris
• patients receiving systemic or topical antipsoroatic treatment in past 3 month
• UV-therapy in past 3 month
• patients having a positive anamnesis for squamous cell carcinoma, malignant melanoma, basalioma
• epilepsy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
PASI, PGA	4 weeks

Secondary Outcome Measures

Name	Time	Method
OCT/ultrasound- thickness of epidermis/ dermis	4 weeks

Trial Locations

Locations (1)

Department of Dermatology, Medical Faculty, TU Dresden; 🇩🇪 Dresden, Germany